Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Litair Pharmaceutical is a specialized pharmaceutical company based in China that focuses on the research, development, and manufacturing of inhalation drug delivery systems. The company specializes in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) through advanced dry powder inhaler (DPI) and metered-dose inhaler (MDI) technologies. Litair operates high-standard manufacturing facilities that comply with international GMP requirements, enabling the production of complex inhaled formulations. Their portfolio includes both generic versions of established respiratory blockbusters and innovative inhalation therapies designed to improve patient compliance and drug efficacy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangsu Litair Pharmaceutical.